Bayer’s Aliqopa gets speedy review for marginal zone lymphomaThe FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) Share XBayer’s Aliqopa gets speedy review for marginal zone lymphomahttps://pharmaphorum.com/news/bayers-aliqopa-gets-speedy-review-for-marginal-zone-lymphoma/
Bayer gains first Aliqopa approval in follicular lymphomaBayer has gained FDA accelerated approval for its follicular lymphoma drug Aliqopa (copanlisib), giving it entry to the Share XBayer gains first Aliqopa approval in follicular lymphomahttps://pharmaphorum.com/news/aliqopa-follicular-lymphoma/
